These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30339716)

  • 1. Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome.
    Deshmukh H; Papageorgiou M; Kilpatrick ES; Atkin SL; Sathyapalan T
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):162-169. PubMed ID: 30339716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
    Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
    Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
    Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
    Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
    Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome.
    Sathyapalan T; Al-Qaissi A; Kilpatrick ES; Dargham SR; Atkin SL
    Clin Endocrinol (Oxf); 2018 Feb; 88(2):258-262. PubMed ID: 29144548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Arch Gynecol Obstet; 2016 Feb; 293(2):447-56. PubMed ID: 26408006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
    Lie Fong S; Laven JSE; Duhamel A; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A pilot study of serum anti-Mullerian hormone in diagnosis of polycystic ovary syndrome based on 2012 Chinese polycystic ovary syndrome diagnosis criteria].
    Yang S; Ruan J; Huang W; Tan J; Zhang X; Feng X; Liu D; Fu J; Zhou L; Zhou M
    Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):819-24. PubMed ID: 26887768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
    Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary and serum androgens with anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome.
    Sathyapalan T; Al-Qaissi A; Kilpatrick ES; Dargham SR; Keevil B; Atkin SL
    Sci Rep; 2018 Feb; 8(1):3795. PubMed ID: 29491484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMH
    Pankhurst MW; Shorakae S; Rodgers RJ; Teede HJ; Moran LJ
    Fertil Steril; 2017 Nov; 108(5):851-857.e2. PubMed ID: 29079276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
    Eilertsen TB; Vanky E; Carlsen SM
    Hum Reprod; 2012 Aug; 27(8):2494-502. PubMed ID: 22693172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold.
    Quinn MM; Kao CN; Ahmad AK; Haisenleder DJ; Santoro N; Eisenberg E; Legro RS; Cedars MI; Huddleston HG;
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):733-740. PubMed ID: 28681949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
    Alebić MŠ; Stojanović N; Duhamel A; Dewailly D
    Hum Reprod; 2015 Aug; 30(8):1927-33. PubMed ID: 26048913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?
    Skałba P; Cygal A; Madej P; Dąbkowska-Huć A; Sikora J; Martirosian G; Romanik M; Olszanecka-Glinianowicz M
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):254-9. PubMed ID: 21752527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women.
    Wongwananuruk T; Panichyawat N; Indhavivadhana S; Rattanachaiyanont M; Angsuwathana S; Techatraisak K; Pratumvinit B; Sa-Nga-Areekul N
    Taiwan J Obstet Gynecol; 2018 Aug; 57(4):499-506. PubMed ID: 30122568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.
    Köninger A; Koch L; Edimiris P; Enekwe A; Nagarajah J; Kasimir-Bauer S; Kimmig R; Strowitzki T; Schmidt B
    Arch Gynecol Obstet; 2014 Nov; 290(5):1023-30. PubMed ID: 24961320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.
    Sova H; Unkila-Kallio L; Tiitinen A; Hippeläinen M; Perheentupa A; Tinkanen H; Puukka K; Bloigu R; Piltonen T; Tapanainen JS; Morin-Papunen L
    Gynecol Endocrinol; 2019 Jul; 35(7):595-600. PubMed ID: 30668196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
    Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
    Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.